Latest Breaking News On - Louie toma - Page 1 : comparemela.com

Indaptus Therapeutics Presents Positive Mechanism of Action Data at the American Association for Cancer Research Annual Meeting

Indaptus Therapeutics Presents Positive Mechanism of Action Data at the American Association for Cancer Research Annual Meeting
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesMichael newmanLouie tomaJeffrey mecklerJules abrahamIndaptus therapeutics incCompany decoyFight tumors directlyAmerican associationCancer researchSan diegoIndaptu founderChief scientific officerIndaptu chief executive officerIndaptus therapeuticsPrivate securities litigation reform

Indaptus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update

Indaptus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Stefan klotterLouie tomaJules abrahamJeffrey mecklerSociety for immunotherapySafety review committeeIndaptus therapeutics incEuropean patent officeAnnounced positive resultsSecond cohortChief executive officerFourth quarterFiscal year ended decemberPrivate securities litigation reformAnnual reportRelations contact

Indaptus Therapeutics Expands Digital Presence with Launch of Social Media Channels

NEW YORK, Feb. 08, 2024 (GLOBE NEWSWIRE) Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical stage biotechnology company dedicated to pion.

Jeffrey mecklerLouie tomaJules abrahamIndaptus therapeutics incIndaptus therapeuticIndaptus therapeuticsLooking statementPrivate securities litigation reformQuarterly reportAnnual reportRelations contact

Kairos Pharma Doses First Patients in Phase 1 Trial of Lead Drug Candidate ENV105 with Osimertinib to Improve Therapy Sensitivity for EGFR-Driven Lung Cancer

Kairos Pharma Doses First Patients in Phase 1 Trial of Lead Drug Candidate ENV105 with Osimertinib to Improve Therapy Sensitivity for EGFR-Driven Lung Cancer
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesLouie tomaJohn yuLos angelesNeil bhowmickKairos pharmaKairos pharma ltdPharma doses first patientsLead drug candidateImprove therapy sensitivityDriven lungChief scientific officerSecurities litigation reform act

AYRO, Inc : AYRO to Showcase Vehicles at 2024 PGA Show

AYRO, Inc : AYRO to Showcase Vehicles at 2024 PGA Show
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesNick kastnerLouie tomaDavid hollingsworthAyro incForum communicationsAmerica golf professionalsEducation summitAnnual report